◎ Sugi Atlas

Atlas / Drug / Dexamethasone

Dexamethasone

drug
On this page

Also known as Aeroseb-dexDecadermDecadronDecadron-75DecasprayDexa-sineDexacortalDexacortinDexacortisylDexafreeDexametasonaDexamethasone component of ciprodexDexamethasone component of dexacidinDexamethasone component of dexasporinDexamethasone component of maxitrolDexamethasone component of tobradexDexamethasone component of tobradex stDexamethasone intensolDexamethasone metasulfobenzoate sodium

Summary

Dexamethasone (CHEMBL384467) is an approved small-molecule immunosuppressive agent (ATC A01AC02) targeting NR1I2, NR3C1, and NR3C2; indicated across 315 conditions including eye disorder and neoplasm; with CIViC clinical evidence for 3 variant-indication associations (e.g. NUP214::ABL1 Fusion in b-lymphoblastic leukemia/lymphoma, bcr-abl1–like).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: A01AC02 (+10 more)
  • Targets: 3 (NR1I2, NR3C1, NR3C2)
  • Indications: 315 conditions
  • Clinical trials: 2,730
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 392.5 Da · C22H29FO5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL384467
NameDexamethasone
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5743
ChEBICHEBI:41879
ATCA01AC02, R01AD03, S02BA06, S03BA01, D07AB19, D10AA03, S01CB01, C05AA09, D07XB05, H02AB02, S01BA01
Molecular formulaC22H29FO5
Molecular weight392.5
InChIKeyUREBDLICKHMUKA-CXSFZGCWSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C

IUPAC name: (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

ChEBI definition: A fluorinated steroid that is 9-fluoropregna-1,4-diene substituted by hydroxy groups at positions 11, 17 and 21, a methyl group at position 16 and oxo groups at positions 3 and 20. It is a synthetic member of the class of glucocorticoids.

Pharmacological roles (ChEBI): immunosuppressive agent, anti-inflammatory drug, adrenergic agent, antiemetic, antineoplastic agent.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Aeroseb-dex, Decaderm, Decadron, Decadron-75, Decaspray, Dexa-sine, Dexacortal, Dexacortin, Dexacortisyl, Dexafree, Dexametasona, Dexamethasone

Patent coverage: 80,451 distinct patent families (279,102 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR1I2Pregnane X receptorAgonist6.10.3%O75469
NR3C1Glucocorticoid receptorAgonist90.9%P04150
NR3C2Mineralocorticoid receptorAgonist90%P08235

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Androgen receptor, Thyrotropin receptor, Inhibitor of nuclear factor kappa-B kinase subunit beta, Mineralocorticoid receptor, Glucocorticoid receptor, Progesterone receptor, Nuclear factor NF-kappa-B complex, Beta-2 adrenergic receptor, Nuclear receptor subfamily 1 group I member 2, Androgen receptor.

Bioactivity

ChEMBL activities: 145 potent at pChembl ≥ 5 of 154 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C110EC500.1nMCHEMBL_ACT_18936145
NR3C110ED500.1nMCHEMBL_ACT_2150545
NR3C19.7EC500.2nMCHEMBL_ACT_1926290
NR3C29.44Ki0.36nMCHEMBL_ACT_13934672
NR3C19.3IC500.5nMCHEMBL_ACT_13845428
NR3C19.3IC500.5nMCHEMBL_ACT_14566761
NFKB19.3IC500.5nMCHEMBL_ACT_26133933
CHUK9.3IC500.5nMCHEMBL_ACT_26133934
IKBKB9.3IC500.5nMCHEMBL_ACT_26133935
NR3C19.29IC500.51nMCHEMBL_ACT_3470274
NR3C19.29IC500.51nMCHEMBL_ACT_3502454
NR3C19.29IC500.51nMCHEMBL_ACT_7851069
NR3C19.16Ki0.69nMCHEMBL_ACT_13934696
NR3C19IC501nMCHEMBL_ACT_14988559
NR3C19EC501nMCHEMBL_ACT_1601065
NR3C19IC501nMCHEMBL_ACT_1977908
NR3C19EC501nMCHEMBL_ACT_2539896
NR3C19IC501nMCHEMBL_ACT_2715556
NR3C19IC501nMCHEMBL_ACT_5199312
NR3C18.96Ki1.1nMCHEMBL_ACT_13439189
NR3C18.96EC501.1nMCHEMBL_ACT_13440450
NR3C18.96EC501.1nMCHEMBL_ACT_13452331
NR3C18.96EC501.1nMCHEMBL_ACT_15024338
NR3C18.96Ki1.1nMCHEMBL_ACT_2517716
NR3C18.96EC501.1nMCHEMBL_ACT_2518486
NR3C18.96EC501.1nMCHEMBL_ACT_2986119
NR3C18.96Ki1.1nMCHEMBL_ACT_3252326
NR3C18.96Ki1.1nMCHEMBL_ACT_6275754
NR3C18.96EC501.1nMCHEMBL_ACT_6276405
NR3C18.93IC501.18nMCHEMBL_ACT_1733236

Target pathways

Aggregated over 3 target gene(s): NR1I2, NR3C1, NR3C2.

Top Reactome pathways

14 total, by targets touching each:

PathwayTargetsGenes
Nuclear Receptor transcription pathway3NR1I2, NR3C1, NR3C2
SUMOylation of intracellular receptors3NR1I2, NR3C1, NR3C2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand2NR3C1, NR3C2
Cellular responses to stress1NR3C2
SUMOylation1NR3C2
SUMO E3 ligases SUMOylate target proteins1NR3C2
Metabolism of proteins1NR3C2
Post-translational protein modification1NR3C2
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
Cellular responses to stimuli1NR3C2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
regulation of DNA-templated transcription3
signal transduction3
negative regulation of transcription by RNA polymerase II2
gene expression2
negative regulation of DNA-templated transcription2
positive regulation of DNA-templated transcription2
positive regulation of transcription by RNA polymerase II2
regulation of transcription by RNA polymerase II2
nuclear receptor-mediated steroid hormone signaling pathway2
xenobiotic metabolic process1
steroid metabolic process1
positive regulation of gene expression1
cell differentiation1
intracellular receptor signaling pathway1
xenobiotic catabolic process1

Indications & clinical

Indications

315 indications (78 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
eye disorder4MONDO:0005328EFO:0005752
neoplasm4MONDO:0005070EFO:0000616
acne4MONDO:0011438EFO:0003894
Crohn disease4MONDO:0005011EFO:0000384
diabetic retinopathy4MONDO:0005266EFO:0003770
gout4MONDO:0005393EFO:0004274
psoriasis4MONDO:0005083EFO:0000676
ulcerative colitis4MONDO:0005101EFO:0000729
Stevens-Johnson syndrome4MONDO:0018229EFO:0004276
contact dermatitis4MONDO:0005480EFO:0005319
meningeal tuberculosis4MONDO:0006042EFO:1000039
erythema multiforme4MONDO:0006545EFO:1000694
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
mycosis fungoides4MONDO:0009691EFO:1001051
peptic ulcer disease4MONDO:0004247HP:0004398
leukemia4MONDO:0005059EFO:0000565
ankylosing spondylitis4MONDO:0005306EFO:0003898
allergic rhinitis4MONDO:0011786EFO:0005854
trichinellosis4MONDO:0019444EFO:0007520
dermatitis herpetiformis4MONDO:0015614EFO:1000684
seborrheic dermatitis4MONDO:0006608EFO:1000764
sympathetic ophthalmia4MONDO:0019198EFO:1001205
tenosynovitis4MONDO:0004855EFO:1001435
non-autoimmune hemolytic anemia4MONDO:0021559EFO:0005558
autoimmune thrombocytopenic purpura4MONDO:0008558EFO:0007160
eosinophilic pneumonia4MONDO:0005749EFO:0007257
iritis4MONDO:0006814EFO:1000997
posterior uveitis4MONDO:0006918EFO:1001119
atopic eczema4MONDO:0004980EFO:0000274
rheumatoid arthritis4MONDO:0008383EFO:0000685
nephrotic syndrome4MONDO:0005377EFO:0004255
aplastic anemia4MONDO:0015909HP:0001915
lymphoma4MONDO:0005062EFO:0000574
atopic conjunctivitis4MONDO:0005642EFO:0007141
optic neuritis4MONDO:0005885EFO:0007405
pulmonary tuberculosis4MONDO:0006052EFO:1000049
thrombocytopenia4MONDO:0002049HP:0001873
pneumonia4MONDO:0005249EFO:0003106
psoriatic arthritis4MONDO:0011849EFO:0003778
pemphigus vulgaris4MONDO:0008219EFO:0004719
subacute thyroiditis4MONDO:0006982EFO:1001194
ophthalmic herpes zoster4MONDO:0005883EFO:0007403
frozen shoulder4MONDO:0006763EFO:1000941
hypercalcemia disease4MONDO:0001566HP:0003072
adrenal gland hyperfunction4MONDO:0006640EFO:1000797
seasonal allergic rhinitis4MONDO:0005324EFO:0003956
synovitis4MONDO:0002400EFO:0008997
keratitis4MONDO:0003085EFO:0009449
exfoliative dermatitis4MONDO:0043233EFO:0009456
hemorrhoid4MONDO:0004872EFO:0009552
myocarditis4MONDO:0004496EFO:0009609
epicondylitis4MONDO:0001875EFO:1001896
iridocyclitis4MONDO:0004773HP:0001094
chorioretinitis4MONDO:0004674HP:0012424
choroiditis4MONDO:0001280MONDO:0001280
dermatitis4MONDO:0002406MONDO:0002406
chronic primary adrenal insufficiency4MONDO:0015129MONDO:0015128
pemphigus4MONDO:0006594EFO:1000749
bursitis4MONDO:0002471MONDO:0002471
type III hypersensitivity disease4MONDO:0007004EFO:1001222
asthma4MONDO:0004979MONDO:0004979
osteoarthritis4MONDO:0005178MONDO:0005178
multiple sclerosis4MONDO:0005301MONDO:0005301
congenital adrenal hyperplasia4MONDO:0018479MONDO:0008728
sarcoidosis4MONDO:0019338MONDO:0019338
adrenal gland disorder4MONDO:0005495EFO:0005539
uveitis4MONDO:0020283EFO:1001231
herpes simplex infectious disease4MONDO:0004609EFO:1002022
systemic lupus erythematosus4MONDO:0007915MONDO:0007915
plasma cell myeloma3MONDO:0009693EFO:0001378
prostate carcinoma3MONDO:0005159EFO:0001663
bronchiolitis3MONDO:0002465HP:0011950
cirrhosis of liver3MONDO:0005155EFO:0001422
breast carcinoma3MONDO:0004989EFO:0000305
HELLP syndrome3MONDO:0008585EFO:0007297
acute respiratory distress syndrome3MONDO:0006502EFO:1000637
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
ovarian carcinoma3MONDO:0005140EFO:0001075
congenital heart disease3MONDO:0005453EFO:0005207
urinary tract infection3MONDO:0100338EFO:0003103
mantle cell lymphoma3MONDO:0018876EFO:1001469
pelvic organ prolapse3MONDO:0000082EFO:0004710
injury3MONDO:0021178EFO:0000546
B-cell acute lymphoblastic leukemia3MONDO:0004947EFO:0000094
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
hepatocellular carcinoma3MONDO:0007256EFO:0000182
Hodgkins lymphoma3MONDO:0004952EFO:0000183
myelodysplastic syndrome3MONDO:0018881EFO:0000198
T-cell acute lymphoblastic leukemia3MONDO:0004963EFO:0000209
acute myeloid leukemia3MONDO:0018874EFO:0000222
colorectal adenocarcinoma3MONDO:0005008EFO:0000365
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
prostate adenocarcinoma3MONDO:0005082EFO:0000673
sarcoma3MONDO:0005089EFO:0000691
small cell lung carcinoma3MONDO:0008433EFO:0000702
malaria3MONDO:0005136EFO:0001068
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
smoldering plasma cell myeloma3MONDO:0005235EFO:0003073
breast neoplasm3MONDO:0021100EFO:0003869
chronic kidney disease3MONDO:0005300EFO:0003884
bacterial vaginosis3MONDO:0005316EFO:0003932
focal segmental glomerulosclerosis3MONDO:0100313EFO:0004236
lymphoid leukemia3MONDO:0005402EFO:0004289
otitis media3MONDO:0005441EFO:0004992
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
plasmacytoma3MONDO:0005615EFO:0006738
cysticercosis3MONDO:0015484EFO:0007231
anterior uveitis3MONDO:0006651EFO:1000811
proliferative vitreoretinopathy3MONDO:0700115EFO:1001129
rotator cuff syndrome3MONDO:0007028EFO:1001250
perennial allergic rhinitis3MONDO:0024332EFO:1001417
precursor T-cell acute lymphoblastic leukemia3MONDO:0020512EFO:1001830
amyloidosis3MONDO:0019065EFO:1001875
soft tissue sarcoma3MONDO:0018078EFO:1001968
sciatica3MONDO:0024333HP:0011868
herpes simplex encephalitis3MONDO:0012521Orphanet:1930
Meniere disease3MONDO:0007972EFO:0006862
lichen planus, oral3MONDO:0043923EFO:0008517
viral conjunctivitis3MONDO:0043541EFO:0008571
neuralgia3MONDO:0021667EFO:0009430
Waldenstrom macroglobulinemia3MONDO:0100280EFO:0009441
blepharitis3MONDO:0004785EFO:0009536
otitis externa3MONDO:0004795EFO:0009560
strabismus3MONDO:0003432HP:0000486
acute erythroid leukemia3MONDO:0017858EFO:0000218
acute monocytic leukemia3MONDO:0007896EFO:0000221
acute myelomonocytic leukemia M43MONDO:0018871EFO:0000223
severe acute respiratory syndrome3MONDO:0005091EFO:0000694
acute megakaryoblastic leukemia3MONDO:0018872EFO:0003025
acute myeloblastic leukemia without maturation3MONDO:0005224EFO:0003027
myelodysplastic syndrome with single lineage dysplasia3MONDO:0005272EFO:0003802
myelodysplastic syndrome with excess blasts3MONDO:0019454EFO:0003811
ovarian neoplasm3MONDO:0021068EFO:0003893
anemia3MONDO:0002280EFO:0004272
viral pneumonia3MONDO:0006012EFO:0007541
chronic myelomonocytic leukemia3MONDO:0020311EFO:1001779
nephrosis3MONDO:0002331MONDO:0002331
ovarian cancer3MONDO:0008170MONDO:0008170
graft versus host disease3MONDO:0013730MONDO:0013730
specific language disorder3MONDO:0016226MONDO:0016226
acute biphenotypic leukemia3MONDO:0020322MONDO:0019460
nasal cavity and paranasal sinus lethal midline granuloma3MONDO:0006828MONDO:0019472
atrioventricular block3MONDO:0000465MONDO:0000465
leiomyoma3MONDO:0001572MONDO:0001572
follicular lymphoma3MONDO:0018906MONDO:0018906
adult acute respiratory distress syndrome3MONDO:0100130MONDO:0100130
mastoiditis3MONDO:0000748HP:0000265
subarachnoid hemorrhage3MONDO:0005099EFO:0000713
male reproductive organ cancer3MONDO:0005836EFO:0007355
primary progressive multiple sclerosis3MONDO:0000451EFO:0008520
corneal edema3MONDO:0006712EFO:1000879
cataract3MONDO:0005129MONDO:0005129
allergic disease3MONDO:0005271MONDO:0005271
migraine disorder3MONDO:0005277MONDO:0005277
sickle cell disease3MONDO:0011382MONDO:0011382
ovarian hyperstimulation syndrome3MONDO:0011972MONDO:0011972
bronchopulmonary dysplasia3MONDO:0019091MONDO:0019091
hereditary amyloidosis3MONDO:0018634MONDO:0019438
obstructive sleep apnea syndrome3MONDO:0007147EFO:0003918
influenza3MONDO:0005812EFO:0007328
glaucoma3MONDO:0005041MONDO:0005041
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
plasma cell neoplasm3MONDO:0004959EFO:0000200
respiratory failure3MONDO:0021113EFO:0009686
female reproductive organ cancer3MONDO:0001416EFO:1001331
colorectal neoplasm3MONDO:0005335MONDO:0005575
wet macular degeneration2MONDO:0005417EFO:0004683
retinal vein occlusion2MONDO:0006951EFO:1001157
melanoma2MONDO:0005105EFO:0000756
lichen planus2MONDO:0006572EFO:1000726
nervous system disorder2MONDO:0005071EFO:0000618
B-cell chronic lymphocytic leukemia2MONDO:0004948EFO:0000095
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
Burkitt lymphoma2MONDO:0007243EFO:0000309
congestive heart failure2MONDO:0005009EFO:0000373
mesothelioma2MONDO:0005065EFO:0000588
myxoid liposarcoma2MONDO:0013280EFO:0000613
renal cell carcinoma2MONDO:0005086EFO:0000681
age-related macular degeneration2MONDO:0005150EFO:0001365
lymphoid neoplasm2MONDO:0005157EFO:0001642
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
hearing loss disorder2MONDO:0005365EFO:0004238
plasma cell leukemia2MONDO:0018689EFO:0006475
appendicitis2MONDO:0005649EFO:0007149
Cryptococcal meningitis2MONDO:0005723EFO:0007228
leptospirosis2MONDO:0005825EFO:0007344
rectal cancer2MONDO:0006519EFO:1000657
dry eye syndrome2MONDO:0006733EFO:1000906
immunoglobulin A vasculitis2MONDO:0019167EFO:1000965
intermediate uveitis2MONDO:0006806EFO:1000986
intracranial hypertension2MONDO:0006810EFO:1000992
POEMS syndrome2MONDO:0017364EFO:1001115
sensorineural hearing loss disorder2MONDO:0020678EFO:1001176
plantar fasciitis2MONDO:0004833EFO:1001909
intrahepatic cholangiocarcinoma2MONDO:0003210EFO:1001961
urothelial carcinoma2MONDO:0040679EFO:0008528
pulmonary fibrosis2MONDO:0002771EFO:0009448
squamous cell lung carcinoma2MONDO:0005097EFO:0000708
cholangiocarcinoma2MONDO:0019087EFO:0005221
oral cavity cancer2MONDO:0005515EFO:0005570
T-cell leukemia2MONDO:0005525EFO:0005592
cerebral toxoplasmosis2MONDO:0005697EFO:0007200
blast phase chronic myelogenous leukemia, BCR-ABL1 positive2MONDO:0006115EFO:1000131
Langerhans cell histiocytosis2MONDO:0018310EFO:1000318
gastric neoplasm2MONDO:0021085MONDO:0001056
brain cancer2MONDO:0001657MONDO:0001657
glomerulonephritis2MONDO:0002462MONDO:0002462
radiculopathy2MONDO:0002959MONDO:0002959
intestinal obstruction2MONDO:0004565MONDO:0004565
lung neoplasm2MONDO:0021117MONDO:0008903
endometrium neoplasm2MONDO:0021251MONDO:0011962
Castleman disease2MONDO:0015564MONDO:0015564
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
pure red-cell aplasia2MONDO:0001705MONDO:0001705
thrombotic thrombocytopenic purpura2MONDO:0018896MONDO:0018896
meningitis2MONDO:0021108MONDO:0021108
endocrine gland neoplasm2MONDO:0002082EFO:0003769
breast carcinoma in situ2MONDO:0004658MONDO:0004658
sinus histiocytosis with massive lymphadenopathy2MONDO:0006412MONDO:0006412
tuberculosis2MONDO:0018076MONDO:0018076
immune system disorder2MONDO:0005046EFO:0000540
heart failure2MONDO:0005252EFO:0003144
obstructive lung disease2MONDO:0002267HP:0006536
gastric adenocarcinoma2MONDO:0005036EFO:0000503
reproductive system disorder2MONDO:0005039EFO:0000512
lung carcinoma2MONDO:0005138EFO:0001071
Lassa fever2MONDO:0005820EFO:0007338
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
tonsillitis2MONDO:0001039MONDO:0001039
pharyngitis2MONDO:0002258MONDO:0002258
optic papillitis2MONDO:0006879MONDO:0004037
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
choroidal neovascularization2MONDO:0810000MONDO:0810000
Graves disease1MONDO:0005364EFO:0004237
primary cutaneous T-cell non-Hodgkin lymphoma1MONDO:0000607EFO:0002913
rheumatic disorder1MONDO:0005554EFO:0005755
head and neck cancer1MONDO:0005627EFO:0006859
brain edema1MONDO:0006684EFO:1000845
aorta coarctation1MONDO:0007345EFO:1001267
vitiligo1MONDO:0008661EFO:0004208
osteoarthritis, knee1MONDO:0005416EFO:0004616
lacrimal apparatus disorder1MONDO:0001854HP:0009926
scleritis1MONDO:0001718MONDO:0001718
adrenocortical insufficiency1MONDO:0000004EFO:0009491
radius fracture1MONDO:0005325EFO:0003957
sinusitis1MONDO:0005961EFO:0007486
retinopathy of prematurity1MONDO:0006952EFO:1001158
anaphylaxis1MONDO:0100053MONDO:0100053
glioblastoma1MONDO:0018177EFO:0000519
pulpitis1MONDO:0006937EFO:1001139
ileus1MONDO:0004567MONDO:0004567
esophageal squamous cell carcinoma1MONDO:0005580EFO:0005922
croup1MONDO:0005722EFO:0007227
hairy cell leukemia1MONDO:0018935EFO:1000956
keratoconus1MONDO:0015486MONDO:0015486
tooth disorder0MONDO:0006999EFO:1001216
hypertensive disorder0MONDO:0005044EFO:0000537
alcohol abuse0MONDO:0002046MONDO:0007079
vestibular neuronitis0MONDO:0006008EFO:0007537

54 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,730.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,730 total).

PhaseTrials
PHASE3532
PHASE2456
PHASE4432
PHASE1/PHASE2111
PHASE2/PHASE369

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01553214PHASE4RECRUITINGImproving White Blood Cell Collection From Healthy Donors
NCT03829371PHASE4ACTIVE_NOT_RECRUITINGSTUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT04025840PHASE4ACTIVE_NOT_RECRUITINGPerioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
NCT04150614PHASE4RECRUITINGBMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
NCT04182997PHASE4RECRUITINGSubjective Intraoperative Use of Epidural Steroid Administration Following Discectomy
NCT04205916PHASE4RECRUITINGA Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery
NCT04432012PHASE4RECRUITINGA Study to Compare Different Ways of Steroid Administration After Total Knee Implantation
NCT04432259PHASE4NOT_YET_RECRUITINGOral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty
NCT04507412PHASE4RECRUITINGIntravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty
NCT04545242PHASE4RECRUITINGEfficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions
NCT04549935PHASE4RECRUITINGThe PRIME Study: A Randomized, Controlled, Prospective Study
NCT04826237PHASE4RECRUITINGOral Statins and Protection From Hearing Loss
NCT05072262PHASE4RECRUITINGDSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)
NCT05191706PHASE4RECRUITINGEvaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05435547PHASE4RECRUITINGPreoperative Corticosteroids in Autoimmune Thyroid Disease
NCT05488847PHASE4ACTIVE_NOT_RECRUITINGOpioid-Free Pain Protocol After Shoulder Arthroplasty
NCT05518383PHASE4RECRUITINGB-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT05522465PHASE4RECRUITINGShort-course High-dose Prednisone and Dexamethasone in Children With ITP
NCT05561725PHASE4RECRUITINGPerioperative Steroid Dosing on the APR in AIS
NCT05716945PHASE4RECRUITINGThe OPTIMISE Study
NCT05721027PHASE4RECRUITINGIbuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
NCT05731960PHASE4RECRUITINGEvaluating the Effect of Intravenous Dexamethasone on the Duration of Spinal Anesthesia After Cesarean Delivery
NCT05824832PHASE4RECRUITINGBuprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery
NCT05936528PHASE4NOT_YET_RECRUITINGLactoferrin Use in ICU Patients
NCT06006624PHASE4ENROLLING_BY_INVITATIONExparel vs Block for ACL Reconstruction
NCT06023043PHASE4NOT_YET_RECRUITINGPostoperative Steroid Use in Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis Patients
NCT06044480PHASE4NOT_YET_RECRUITINGEffect of Dexamethason on Postimplantation Syndrome After EVAR
NCT06118710PHASE4RECRUITINGEvaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment
NCT06160180PHASE4NOT_YET_RECRUITINGComparative Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone on Postoperative Complications Following Surgical Extraction of Mandibular Third Molar: Randomized Controlled Trial
NCT06268704PHASE4RECRUITINGParticulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection
NCT06289673PHASE4RECRUITINGIdentification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT06367855PHASE4RECRUITINGEfficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF
NCT06404541PHASE4ACTIVE_NOT_RECRUITINGA Comparative Study Between Preservative With Benzalkonium Chloride vs Preservative Free Eye Drops on the Ocular Surface
NCT06408974PHASE4NOT_YET_RECRUITINGComparison Between Ketamine Intrathecal and iv Dexamethasone for Post Cesarean Analgesia
NCT06409702PHASE4RECRUITINGTreatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06465992PHASE4ENROLLING_BY_INVITATIONLiposomal Bupivacaine With Dexamethasone for Foot Surgery
NCT06575010PHASE4ENROLLING_BY_INVITATIONExparel v Dexamethasone in RCR
NCT06603662PHASE4RECRUITINGSystemic Oral Glucocorticoids for the Treatment of Acute Osteoarthritis Pain in the Emergency Department
NCT06624436PHASE4RECRUITINGImmunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
NCT06685991PHASE4NOT_YET_RECRUITINGEffect of Timing of Dexamethasone During Induction on Postoperative Outcomes

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
NUP214::ABL1 FusionB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSensitivity/ResponseVincristine + Dexamethasone + DasatinibCIViC CEID7208
CDK4 EXPRESSIONChildhood B-cell Acute Lymphoblastic LeukemiaSensitivity/ResponseRibociclib + DexamethasoneCIViC DEID7798
CDK6 EXPRESSIONChildhood B-cell Acute Lymphoblastic LeukemiaSensitivity/ResponseDexamethasone + RibociclibCIViC DEID7801

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 14 clinical and 55 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

379 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ENZALUTAMIDEChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1, NR3C2
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR1I2, NR3C1, NR3C2
MIFEPRISTONEChEMBLPhase 4 (approved)NR1I2, NR3C1, NR3C2
PROGESTERONEChEMBLPhase 4 (approved)NR1I2, NR3C1, NR3C2
BOSENTANChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
EPLERENONEChEMBL + PubChemPhase 4 (approved)NR3C1, NR3C2
FLUDROCORTISONEChEMBL + PubChemPhase 4 (approved)NR3C1, NR3C2
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
TADALAFILChEMBL + PubChemPhase 4 (approved)NR1I2, NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR1I2, NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR1I2, NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR1I2, NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1, NR3C2
BUTOCONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR1I2, NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR1I2, NR3C1
CLOBETASOL PROPIONATEChEMBLPhase 4 (approved)NR1I2, NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
DANAZOLChEMBLPhase 4 (approved)NR1I2, NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR1I2, NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR1I2, NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR1I2, NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR1I2, NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR1I2, NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR1I2, NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR1I2, NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR1I2, NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1, NR3C2
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C1, NR3C2
HYDROCORTISONE BUTYRATEChEMBLPhase 4 (approved)NR3C1, NR3C2
HYDROXYPROGESTERONE CAPROATEChEMBLPhase 4 (approved)NR1I2, NR3C1
ISOCONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
ISRADIPINEChEMBLPhase 4 (approved)NR1I2, NR3C1
KETOCONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
LASOFOXIFENEChEMBLPhase 4 (approved)NR1I2, NR3C1
LOTEPREDNOL ETABONATEChEMBLPhase 4 (approved)NR1I2, NR3C1
MASOPROCOLChEMBLPhase 4 (approved)NR1I2, NR3C1
MEDROXYPROGESTERONEChEMBLPhase 4 (approved)NR3C1, NR3C2
METHYLPREDNISOLONEChEMBLPhase 4 (approved)NR1I2, NR3C1
MICONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
MITOTANEChEMBLPhase 4 (approved)NR1I2, NR3C1
NAFTOPIDILChEMBLPhase 4 (approved)NR1I2, NR3C1
NIMODIPINEChEMBLPhase 4 (approved)NR1I2, NR3C1
NISOLDIPINEChEMBLPhase 4 (approved)NR1I2, NR3C1
NORGESTIMATEChEMBLPhase 4 (approved)NR1I2, NR3C1
PONATINIBChEMBLPhase 4 (approved)NR1I2, NR3C1
PREDNISOLONEChEMBLPhase 4 (approved)NR3C1, NR3C2
RACECADOTRILChEMBLPhase 4 (approved)NR1I2, NR3C1
RIMEXOLONEChEMBLPhase 4 (approved)NR1I2, NR3C1
SIMVASTATINChEMBLPhase 4 (approved)NR1I2, NR3C1
SPIRONOLACTONEChEMBLPhase 4 (approved)NR3C1, NR3C2
SULCONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
TAMOXIFENChEMBLPhase 4 (approved)NR1I2, NR3C1
TESTOSTERONE PROPIONATEChEMBLPhase 4 (approved)NR1I2, NR3C1
TIOCONAZOLEChEMBLPhase 4 (approved)NR1I2, NR3C1
TOLCAPONEChEMBLPhase 4 (approved)NR1I2, NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot